Aktiesnakken — Juni 2013
-
De sidste holder jeg fordi jeg trods alt stadig har lidt fidus til at deres produkter kan slå igennem. Men nu er jeg uden risiko i den
-
Aka omsætningen i Zeal er ikke imponerende. Kan være rebound
-
Velo i 0,66
-
var der ikke snak om kræftrisiko ved heleplatformen
-
Så faldt Zea også igen
-
Stigningen imorges var under lav omsætning
-
Genmab ska leje med 220 i denne uge
-
novo....din bastard
-
Aktietilbagkeøbsprogrammet
-
nej dårlige nyheder er ikke noget nyt for novo
-
Genmab rammer 220 allerede idag
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind